High tigecycline resistance in multidrug-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 772-774

  Navon Venezia, Shiri ^a   Leavitt, Azita ^a   Carmeli, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotic resistance; Etest; Glycylcyclines; MDR multiple clones

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; ANTIINFECTIVE AGENT; DRUG DERIVATIVE;

ACINETOBACTER BAUMANNII; ANALYTIC METHOD; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG CHOICE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; SPECIES IDENTIFICATION; BACTERIAL INFECTION; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TETRACYCLINE RESISTANCE;

EID: 34249977996     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm018     Document Type: Article

References (12)

1. Quale J, Bratu S, Landman D et al. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New-York City. Clin Infect Dis 2003; 37: 214-20.
2. Van Looveren M, Goossens H, the ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
3. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
4. Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States. Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52 173-9.
5. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2002; 48: 4479-81.
6. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50: 3166-69.
7. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin structure infection and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-32.
8. Talbot GH, Bradley J, Edwards JE, Jr et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
9. Abbo A, Navon-Venezia S, Hammer-Muntz O et al. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11: 22-9.
10. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007; 59: 128-31.
11. Sahm DF, Dowzicky MJ, Draghi DC et al. Surveillance of tigecycline activity; discordance between national profiles associated with testing protocols and methods. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract D-701. American Society for Microbiology, Washington, DC, USA.
12. Lolans K, Rice TW, Munoz-Pdce S et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50 2941-45.